Enzymotec Ltd. Reports a Decision of the U.S. Patent and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Enzymotec Ltd. Reports a Decision of the U.S. Patent and Trademark Office

MIGDAL HA'EMEQ, Israel, March 24, 2015 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY ) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, reported today that on March 23, 2015 the US Patent and Trademark Office ("USPTO") issued a decision in an Inter Partes Review ("IPR") of Neptune Technologies & Bioressources' ("Neptune") U.S. Patent No. 8,278,351 ('351 patent). The USPTO determined that 26 out of 28 challenged claims in the '351 patent are unpatentable. Enzymotec intends to appeal the USPTO decision regarding the two remaining challenged claims.

According to the final settlement and license agreement that was signed between Enzymotec and Neptune in April 2014, Enzymotec has a worldwide non-exclusive license to the entire 8,030,348 patent family of Neptune, which includes the '351 patent, for as long as any patent in that family exists, for all of the Company's relevant current products and future anticipated products under development.

Neptune is not entitled to any royalty payments in North America under the agreement, unless the final outcome, following an appeal, of the IPR of Neptune's '351 patent is unfavorable to Enzymotec.

Dr. Ariel Katz, President and Chief Executive Officer of Enzymotec, commented, "We are pleased that almost all of the challenged claims in the IPR were determined unpatentable by the USPTO and we intend to challenge the patentability of the two remaining claims. Our recently granted patents and our license for Neptune's patents have strengthened our portfolio of intellectual property and will limit other players from entering the competitive krill oil market. Our products remain market leaders, bolstered by our specialized technologies and innovation, providing our customers with exceptional ingredients of the highest quality in the market."

The '351 patent is also the subject of an ex parte reexamination, which has been stayed pending a decision in the '351 IPR. Prior to the ex parte reexamination being stayed, the USPTO rejected all claims of the '351 patent in a non-final office action.  Neptune will have an opportunity to respond to that decision once the stay is lifted.

With respect to Neptune's patent in Australia, on January 28, 2015 the Australian Patent Office issued a reexamination report in response to Enzymotec's request, finding that all the agreed claims in the patent lack novelty. Neptune has until March 28, 2015 to overcome the examiner's report, either by arguments or amendments. All the agreed claims in Australia correspond to claims that were determined unpatentable by the USPTO in the '351 IPR. If the final outcome remains favorable to Enzymotec, no royalty payments will be paid by Enzymotec to Neptune in Australia.  

About Enzymotec Ltd.

Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com

Forward-Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include the following risks: A high proportion of the sales of the InFat product is sold to end users in China and to a single company; The demand for products based on Omega-3 and in particular, premium products, such as krill oil, has declined and may continue to decline following a significant increase in manufacturing capacity by manufacturers of these products, resulting in intense competition and price pressure; Our offering of products as "medical foods" in the United States may be challenged by regulatory authorities; We rely on our Swedish joint venture partner to manufacture InFat and certain matters related to the joint venture are the subject of disagreement in arbitration proceeding; We are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments with us; We depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products; We are dependent on a single facility that houses the majority of our operations; We may have to pay royalties with respect to sales of our krill oil products in the United States or Australia and any infringement of intellectual property of others could also require us to pay royalties; Potential future acquisitions of companies or technologies may distract our management, may disrupt our business and may not yield the returns expected; We anticipate that the markets in which we participate will become more competitive and we may be unable to compete effectively; We may not be able to successfully expand our production or processing capabilities; Our ability to obtain krill may be affected by conservation regulation or initiatives; Our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; and other factors discussed under the heading "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission on March 2, 2015. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. 

KCSA Strategic Communications Jeffrey Goldberger / Tram Bui 212.896.1249 / 212.896.1290

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 98

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading

Top 5 Most Recently Viewed Articles

Ross Gerber Expresses Optimism for Meta's Phone-Free Future

Updated Category News Views 242

Ross Gerber Praises Meta's Smart Glasses Technology Over the weekend, investor Ross Gerber expressed his admiration for Meta Platforms, Inc. (NASDAQ: META) smart glasses, affirming their potential to transform our relationship with technology. Gerber noted that this innovative eyewear gives him hope for a day when he might no longer rely on his smartphone. Smart Glasses:...

Continue Reading
Organ-on-a-Chip Market Insights and Future Projections

Updated Category News Views 118

Understanding the Organ-on-a-Chip Market Growth As technology evolves, the quest for more accurate and human-relevant drug testing models takes center stage. The Organ-on-a-Chip (OOC) market has emerged as a revolutionary force, previously valued at around USD 117.67 million, and now set to skyrocket to approximately USD 1.64 billion by 2032. This innovative approach is...

Continue Reading
Discovering Blue Light Cystoscopy Benefits in Bladder Cancer

Updated Category News Views 240

New Insights on Blue Light Cystoscopy and Bladder Cancer Photocure ASA, known as the Bladder Cancer Company, has made significant advancements in bladder cancer management with the recent study titled "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO Study." This research published in JU Open Plus provides compelling evidence...

Continue Reading
BioCryst's Bold Move: Astria Therapeutics Acquisition Insights

Updated Category News Views 211

BioCryst Enhances HAE Portfolio with Astria Acquisition BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant announcement regarding its acquisition of Astria Therapeutics, Inc. (NASDAQ: ATXS). This strategic move will strengthen BioCryst's position in the hereditary angioedema (HAE) market, as they plan to integrate Astria's promising therapies and...

Continue Reading
Milestone Scientific Reaches New Height with Strong Growth

Updated Category News Views 361

Milestone Scientific Achieves 52-Week High Milestone Scientific Inc. (NYSE: MLSS) has reached a significant milestone with its stock trading at $1.28, marking a 52-week high. This impressive achievement highlights the company's robust annual growth and increased investor confidence. As a result, the current market capitalization has reached approximately $97.37 million,...

Continue Reading